Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of JNJ-64530440 with Oral Contraceptives and Midazolam in Healthy Females
NCT03890341Phase 1Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Jun 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of JNJ-64530440 in Chronic Hepatitis B (CHB), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Observed Plasma Analyte Concentration of Drospirenone, Area Under the Plasma Analyte Concentration-Time Curve from Time Zero to Last Quantifiable Concentration Time of Drospirenone and 4 more. Planned start Jun 2021; status: withdrawn.
02
Drugs
JNJ-64530440
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03890341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03890341.